{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T14:07:49Z","timestamp":1787580469003,"version":"build-2736575974"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T00:00:00Z","timestamp":1750982400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Hepatoid adenocarcinoma of the stomach (HAS) is a rare but highly aggressive subtype of gastric cancer (GC) associated with an unfavorable prognosis, particularly in advanced or metastatic stages. While the standard first-line treatment for advanced GC involves immune checkpoint inhibitors (ICIs) combined with chemotherapy, HAS often shows a poor therapeutic response to this regimen. The hypoxia in the tumor microenvironment is considered a key factor limiting ICI efficacy, and combining hyperbaric oxygen therapy (HBOT) with immunotherapy may offer a synergistic sensitizing effect.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We report a case of advanced HAS with peritoneal metastasis who received standard first-line immunochemotherapy (CAPOX plus sintilimab). After four cycles, the patient achieved only stable disease (SD) per RECIST 1.1 criteria. Consequently, HBOT was introduced as a sensitizing agent after the fifth cycle, and the patient subsequently completed the sixth cycle. This report was prepared using the CARE reporting guideline and checklist (Supplement A).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Following the addition of HBOT, the patient\u2019s tumor markers normalized. Subsequent imaging and endoscopic evaluations revealed a complete resolution of all lesions, meeting the criteria for a clinical complete response (cCR) under RECIST 1.1.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>This case suggests that adding HBOT may enhance the efficacy of immunotherapy and overcome resistance to ICIs in advanced HAS. These promising findings warrant further investigation through prospective clinical studies to confirm this observation.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2025.1625273","type":"journal-article","created":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T09:34:37Z","timestamp":1751016877000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Hyperbaric oxygen therapy as an immunosensitizing strategy in advanced gastric hepatoid adenocarcinoma: a case report"],"prefix":"10.3389","volume":"16","author":[{"given":"Wenke","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengfei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mo","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Menghui","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,6,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.12336","article-title":"Genomic profiling and the impact of MUC19 mutation in hepatoid adenocarcinoma of the stomach","volume":"42","author":"Zhu","year":"2022","journal-title":"Cancer Commun (Lond)"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.633916","article-title":"Hepatoid adenocarcinoma of the stomach: current perspectives and new developments","volume":"11","author":"Xia","year":"2021","journal-title":"Front Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjsurg.2022.01.024","article-title":"Patterns of gastric cancer metastasis in the United States","volume":"224","author":"Sirody","year":"2022","journal-title":"Am J Surg"},{"key":"B4","doi-asserted-by":"publisher","first-page":"e2100233","DOI":"10.1002\/advs.202100233","article-title":"Hyperbaric oxygen boosts PD-1 antibody delivery and T cell infiltration for augmented immune responses against solid tumors","volume":"8","author":"Liu","year":"2021","journal-title":"Adv Sci (Weinh)"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2023.216104","article-title":"Hepatoid adenocarcinoma-Clinicopathological features and molecular characteristics","volume":"559","author":"Li","year":"2023","journal-title":"Cancer Lett"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00515-6","article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial","volume":"24","author":"Rha","year":"2023","journal-title":"Lancet Oncol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","article-title":"First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial","volume":"398","author":"Janjigian","year":"2021","journal-title":"Lancet"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.19918","article-title":"Sintilimab plus chemotherapy for unresectable gastric or gastroesophageal junction cancer: the ORIENT-16 randomized clinical trial","volume":"330","author":"Xu","year":"2023","journal-title":"Jama"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1566939","article-title":"The efficacy and safety of PD-1\/PD-L1 inhibitors in combination with chemotherapy as a first-line treatment for unresectable, locally advanced, HER2-negative gastric or gastroesophageal junction cancer: a meta-analysis of randomized controlled trials","volume":"16","author":"Pu","year":"2025","journal-title":"Front Immunol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"5554","DOI":"10.7150\/ijbs.71449","article-title":"Integrative analysis reveals a clinicogenomic landscape associated with liver metastasis and poor prognosis in hepatoid adenocarcinoma of the stomach","volume":"18","author":"Jiang","year":"2022","journal-title":"Int J Biol Sci"},{"key":"B12","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s10120-024-01562-x","article-title":"Volume of hepatoid component and intratumor M2 macrophages predict prognosis in patients with hepatoid adenocarcinoma of the stomach","volume":"28","author":"Taniguchi","year":"2025","journal-title":"Gastric Cancer"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.901061","article-title":"Elevated serum alpha-fetoprotein is a significant prognostic factor for patients with gastric cancer: Results based on a large-scale retrospective study","volume":"12","author":"Zhan","year":"2022","journal-title":"Front Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-002-1099-y","article-title":"Evaluation of VEGF and VEGF-C expression in gastric cancer cells producing \u03b1-fetoprotein","volume":"38","author":"Kamei","year":"2003","journal-title":"J Gastroenterol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"152454","DOI":"10.1016\/j.prp.2019.152454","article-title":"ANGPTL6-mediated angiogenesis promotes alpha fetoprotein-producing gastric cancer progression","volume":"215","author":"Chen","year":"2019","journal-title":"Pathol-Res Pract"},{"key":"B16","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1038\/s41392-023-01332-8","article-title":"Hypoxic microenvironment in cancer: molecular mechanisms and therapeutic interventions","volume":"8","author":"Chen","year":"2023","journal-title":"Signal Transduction Targeted Ther"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.2003.015032","article-title":"The role of hypoxia inducible factor 1 (HIF-1) in hypoxia induced apoptosis","volume":"57","author":"Greijer","year":"2004","journal-title":"J Clin Pathol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1187","article-title":"Targeting HIF-1 for cancer therapy","volume":"3","author":"Semenza","year":"2003","journal-title":"Nat Rev Cancer"},{"key":"B19","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.canlet.2022.01.027","article-title":"HIF-1\u03b1 inhibition promotes the efficacy of immune checkpoint blockade in the treatment of non-small cell lung cancer","volume":"531","author":"Luo","year":"2022","journal-title":"Cancer Lett"},{"key":"B20","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s13045-021-01102-5","article-title":"The relationship between expression of PD-L1 and HIF-1\u03b1 in glioma cells under hypoxia","volume":"14","author":"Ding","year":"2021","journal-title":"J Hematol Oncol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"e159473","DOI":"10.1172\/JCI159473","article-title":"Cross-talk between HIF and PD-1\/PD-L1 pathways in carcinogenesis and therapy","volume":"132","author":"Shurin","year":"2022","journal-title":"J Clin Invest"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.2353\/ajpath.2010.091021","article-title":"Hypoxia increases the expression of stem-cell markers and promotes clonogenicity in glioblastoma neurospheres","volume":"177","author":"Bar","year":"2010","journal-title":"Am J Pathol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"399","DOI":"10.7150\/ijms.5407","article-title":"Hypoxia enhances stemness of cancer stem cells in glioblastoma: an in vitro study","volume":"10","author":"Li","year":"2013","journal-title":"Int J Med Sci"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.691762","article-title":"Hyperbaric oxygen therapy represses the Warburg effect and epithelial\u2013mesenchymal transition in hypoxic NSCLC cells via the HIF-1\u03b1\/PFKP axis","volume":"11","author":"Zhang","year":"2021","journal-title":"Front Oncol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1038\/s41420-021-00486-0","article-title":"Hyperbaric oxygen promotes not only glioblastoma proliferation but also chemosensitization by inhibiting HIF1\u03b1\/HIF2\u03b1-Sox2","volume":"7","author":"Wang","year":"2021","journal-title":"Cell Death Discov"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1700859","DOI":"10.1002\/advs.201700859","article-title":"Hyperbaric oxygen potentiates doxil antitumor efficacy by promoting tumor penetration and sensitizing cancer cells","volume":"5","author":"Wu","year":"2018","journal-title":"Adv Sci"},{"key":"B27","doi-asserted-by":"publisher","first-page":"12033","DOI":"10.1038\/s41598-021-91454-2","article-title":"Hyperbaric oxygen suppressed tumor progression through the improvement of tumor hypoxia and induction of tumor apoptosis in A549-cell-transferred lung cancer","volume":"11","author":"Chen","year":"2021","journal-title":"Sci Rep"},{"key":"B28","doi-asserted-by":"publisher","first-page":"e004006","DOI":"10.1136\/jitc-2021-004006","article-title":"Hyperbaric oxygen facilitates teniposide-induced cGAS-STING activation to enhance the antitumor efficacy of PD-1 antibody in HCC","volume":"10","author":"Li","year":"2022","journal-title":"J ImmunoTher Cancer"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2023.1082057","article-title":"The hypoxia-inducible factor-1\u03b1 in stemness and resistance to chemotherapy in gastric cancer: Future directions for therapeutic targeting","volume":"11","author":"Ozcan","year":"2023","journal-title":"Front Cell Dev Biol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1625273\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T09:34:37Z","timestamp":1751016877000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1625273\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,27]]},"references-count":29,"alternative-id":["10.3389\/fimmu.2025.1625273"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1625273","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,27]]},"article-number":"1625273"}}